1.	Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
2.	Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: HEMOS AML 0106, EudraCT 2007-000273-35, NCT00510939
3.	Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCRR Protocol IDs: NCRR-M01RR00096-1001, M01RR00096, NCT00006199